Phase 3 Head and Neck Cancer Trial, Recruiting NCT07340515 Sponsor: Man Hu Condition: Head and Neck Cancer
Back to Head And Neck Cancer

Phase 3 Head and Neck Cancer Trial, Recruiting

NCT07340515
Recruiting Phase 3

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • Adults between 18 and 70 years of age
  • People with a laboratory-confirmed diagnosis of nasopharyngeal carcinoma (a type of cancer at the back of the nose and throat), specifically WHO type II or III
  • People whose cancer is classified as high-risk locally advanced disease, meaning it has reached a stage called T4 or N3 but has not spread to distant parts of the body (confirm staging details with trial site)
  • People who have not yet received any treatment for nasopharyngeal carcinoma, including radiation, chemotherapy, targeted therapy, or immunotherapy
  • People with a good general level of physical functioning, rated 0 or 1 on a standard medical scale where 0 means fully active and 1 means minor limitations (confirm with trial site)
  • People whose heart, liver, kidneys, and other organs are working well enough to meet the study's health requirements (confirm specific values with trial site)
  • People whose treating doctor determines they are suitable to receive the combination of chemotherapy and radiation with immunotherapy used in this trial
  • People who are willing and able to read and sign a consent form agreeing to take part

Who may not be able to join:

  • People whose cancer has already spread to distant parts of the body
  • People who have already received any form of treatment for nasopharyngeal carcinoma
  • People who have an active autoimmune disease that currently requires ongoing medical treatment
  • People with an uncontrolled infection or serious health conditions that could make tolerating the treatment difficult
  • People who are pregnant or currently breastfeeding
  • People with a known allergy, severe sensitivity, or medical reason to avoid any of the medications used in this study (confirm specifics with trial site)
  • People who, in the trial doctor's judgment, have any other condition that makes participation unsuitable

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 16 July 2026
Phase 3: approximately ~65% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.
Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Phase 3
Sponsor
Man Hu
Registry
ClinicalTrials.gov
Start date
15 December 2025
Est. completion
31 December 2031

Where this trial is recruiting

🇨🇳 China

Primary endpoints

Incidence of treatment-related grade ≥3 acute toxicities; 3-year Progression-Free Survival (PFS) Rate

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 16 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov